BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
back to Directory

SiSaf

SiSaf logo

Website
https://sisaf.com/
Founded
2008

We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.
Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships.

Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.


Posts Mentioning This Company

RNA Interference Technology: FDA Approves SiSaf's siRNA Therapy, SIS-101-ADO | Autosomal Dominant Osteopetrosis Treatment

FDA Recognizes SiSaf's siRNA Therapy, SIS-101-ADO, for Autosomal Dominant Osteopetrosis Treatment

May 16, 2023  
In a noteworthy development in the pharmaceutical industry, SiSaf Ltd, a renowned RNA delivery and therapeutics firm, recently announced that the U.S. FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its novel siRNA therapeutic, SIS-101-ADO, for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

News

  • 2023-12-18
    SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier® Technology

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.